Importantly, IL20RB neutralization with antibodies reduced the metastatic potential of tumor cells in vivo; therefore this becomes a relevant strategy to be evaluated in clinical trials in order to manage bone metastases in advanced stages. Here, IL20RB is linked to neoplasm.